{"doi":"10.2957/kanzo.24.508","title":"","abstract":null,"journal":"Kanzo","year":1983,"id":596534,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1527818,"name":"Hiroko TSUTSUI","orcid":null,"position":1,"is_corresponding":false},{"id":1527819,"name":"Yoshihide SAKAGAMI","orcid":null,"position":2,"is_corresponding":false},{"id":1527820,"name":"Takashi SHIBA","orcid":null,"position":3,"is_corresponding":false},{"id":1527821,"name":"Yasuhiro MIZOGUCHI","orcid":null,"position":4,"is_corresponding":false},{"id":1527822,"name":"Takeyuki MONNA","orcid":null,"position":5,"is_corresponding":false},{"id":1527823,"name":"Sukeo YAMAMOTO","orcid":null,"position":6,"is_corresponding":false},{"id":1527824,"name":"Seiji MORISAWA","orcid":null,"position":7,"is_corresponding":false},{"id":1527816,"name":"Toshihiro HIGASHIMORI","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":null,"abstract":"肝疾患患者末梢血単球系細胞をeffector細胞とし,正常ラット肝から調製した分離肝細胞を標的細胞として,抗肝細胞膜抗体を介するantibody-dependent cell-mediated cytotox-icity (ADCC)を検討した,急性肝炎,慢性活動性肝炎患者の単球系細胞はADCC反応のeffector細胞の機能を備えていたが,肝硬変,肝癌患者の単球系細胞は,機能の低下,または欠除の状態にあることが認められた.つぎに,単球系細胞をlipopolysaccharideで活性化して同様にADCC反応のeffector細胞として用いると,慢性活動性肝炎患者単球系細胞は,非活性化時に比較して細胞障害性が亢進したが,肝硬変,肝癌では,一部に細胞障害活性の亢進を認めたのみで,大部分は変化を認めなかった.以上の成績から,慢性活動性肝炎では,末梢血単球系細胞をeffector細胞とするADCC反応が生起しうる可能性が示唆されたが,各種肝疾患の病態に応じて,effector細胞としての末梢血単球系細胞の機能は異なることが認められた.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21097893","pmcid":null,"openalex_id":"https://openalex.org/W4249181383","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.33128168,"influential_citations":0,"citation_trend":[],"oa_status":"bronze","license":null,"oa_locations":[{"url":"https://www.jstage.jst.go.jp/article/kanzo1960/24/5/24_5_508/_pdf","host_type":"journal"},{"url":"https://www.jstage.jst.go.jp/article/kanzo1960/24/5/24_5_508/_pdf","host_type":"publisher"},{"url":"http://www.jstage.jst.go.jp/article/kanzo1960/24/5/24_5_508/_pdf","host_type":"publisher"},{"url":"https://doi.org/10.2957/kanzo.24.508","host_type":"journal"}],"fields_of_study":["Immune Cell Function and Interaction","Glycosylation and Glycoproteins Research","Diabetes and associated disorders"],"mesh_terms":[],"keywords":["Antibody-dependent cell-mediated cytotoxicity","Effector","Biology","Immunology","Antibody","Monoclonal antibody"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T10:34:57.244741Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}